$EYPT
EyePoint Pharmaceuticals, Inc.

2015 Form 10-K Financial Statement

#000119312515316983 Filed on September 10, 2015

View on sec.gov

Income Statement

Concept 2015 2014 Q2 2014 Q1
Revenue $26.57M $292.0K $1.992M
YoY Change 664.9% -40.65% 288.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.060M $2.000M $1.950M
YoY Change 7.9% -6.98% 12.07%
% of Gross Profit
Research & Development $12.09M $2.310M $2.269M
YoY Change 26.27% -0.43% 42.97%
% of Gross Profit
Depreciation & Amortization $112.0K $240.0K $220.0K
YoY Change -19.42% -4.0% -12.0%
% of Gross Profit
Operating Expenses $20.14M $4.300M $4.211M
YoY Change 18.75% -3.8% 26.65%
Operating Profit $6.421M -$4.012M -$2.219M
YoY Change -147.6% 0.78% -21.09%
Interest Expense $20.00K $0.00 $0.00
YoY Change 100.0%
% of Operating Profit 0.31%
Other Income/Expense, Net $22.00K $0.00 $1.000K
YoY Change 340.0% -66.67%
Pretax Income $6.443M -$4.010M -$2.218M
YoY Change -147.78% 0.75% -21.04%
Income Tax $96.00K -$40.00K -$31.00K
% Of Pretax Income 1.49%
Net Earnings $6.347M -$3.967M -$2.187M
YoY Change -147.53% 0.51% -21.73%
Net Earnings / Revenue 23.89% -1358.56% -109.79%
Basic Earnings Per Share $0.22 -$0.08
Diluted Earnings Per Share $0.21 -$1.355M -$0.08
COMMON SHARES
Basic Shares Outstanding 29.38M shares 29.25M shares 27.67M shares
Diluted Shares Outstanding 30.58M shares 27.67M shares

Balance Sheet

Concept 2015 2014 Q2 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.50M $18.30M $21.30M
YoY Change 55.74% 77.67% 55.47%
Cash & Equivalents $19.10M $15.33M $18.56M
Short-Term Investments $9.400M $2.900M $2.700M
Other Short-Term Assets $700.0K $500.0K $600.0K
YoY Change 40.0% -68.75% 20.0%
Inventory
Prepaid Expenses
Receivables $600.0K $500.0K $600.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $29.80M $19.34M $22.46M
YoY Change 54.4% 55.18% 47.73%
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K $297.0K $292.0K
YoY Change 0.0% 65.92% 30.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $300.0K $300.0K
YoY Change 0.0% 50.0% 200.0%
Total Long-Term Assets $2.600M $3.329M $3.559M
YoY Change -23.53% -12.05% -9.09%
TOTAL ASSETS
Total Short-Term Assets $29.80M $19.34M $22.46M
Total Long-Term Assets $2.600M $3.329M $3.559M
Total Assets $32.40M $22.67M $26.02M
YoY Change 42.73% 39.52% 36.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $700.0K $464.0K $761.0K
YoY Change 40.0% -30.85% 114.37%
Accrued Expenses $2.600M $1.524M $1.203M
YoY Change 73.33% -19.54% -16.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.300M $2.126M $2.276M
YoY Change 57.14% -35.63% -15.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.700M $5.600M $5.400M
YoY Change 1.79% 7.69% 3.85%
Total Long-Term Liabilities $5.700M $5.600M $5.400M
YoY Change 1.79% 7.69% 3.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.300M $2.126M $2.276M
Total Long-Term Liabilities $5.700M $5.600M $5.400M
Total Liabilities $9.000M $7.747M $7.675M
YoY Change 16.88% -9.38% -2.59%
SHAREHOLDERS EQUITY
Retained Earnings -$277.0M -$273.0M
YoY Change 5.07% 5.13%
Common Stock $290.9M $29.00K
YoY Change 1264652.17% 26.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.40M $14.92M $18.35M
YoY Change
Total Liabilities & Shareholders Equity $32.40M $22.67M $26.02M
YoY Change 42.73% 39.52% 36.09%

Cashflow Statement

Concept 2015 2014 Q2 2014 Q1
OPERATING ACTIVITIES
Net Income $6.347M -$3.967M -$2.187M
YoY Change -147.53% 0.51% -21.73%
Depreciation, Depletion And Amortization $112.0K $240.0K $220.0K
YoY Change -19.42% -4.0% -12.0%
Cash From Operating Activities $10.30M -$2.780M -$1.860M
YoY Change -196.53% -17.75% -5.58%
INVESTING ACTIVITIES
Capital Expenditures $161.0K -$170.0K -$60.00K
YoY Change -35.08% 750.0% 500.0%
Acquisitions
YoY Change
Other Investing Activities -$6.570M -$250.0K -$2.210M
YoY Change -2219.35% -110.87% -481.03%
Cash From Investing Activities -$6.730M -$420.0K -$2.260M
YoY Change -9714.29% -118.42% -503.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $7.000M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 240.0K -20.00K 7.460M
YoY Change -98.74%
NET CHANGE
Cash From Operating Activities 10.30M -2.780M -1.860M
Cash From Investing Activities -6.730M -420.0K -2.260M
Cash From Financing Activities 240.0K -20.00K 7.460M
Net Change In Cash 3.810M -3.220M 3.340M
YoY Change -54.86% 192.73% -336.88%
FREE CASH FLOW
Cash From Operating Activities $10.30M -$2.780M -$1.860M
Capital Expenditures $161.0K -$170.0K -$60.00K
Free Cash Flow $10.14M -$2.610M -$1.800M
YoY Change -192.86% -22.32% -8.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q1 psdv Common Stock Warrant Exercise Price Per Share
CommonStockWarrantExercisePricePerShare
5.00
CY2013Q3 us-gaap Share Price
SharePrice
3.10
CY2012Q3 psdv Common Stock Warrant Exercise Price Per Share
CommonStockWarrantExercisePricePerShare
2.50
CY2014Q4 dei Entity Public Float
EntityPublicFloat
118606000
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29417365 shares
CY2014Q1 us-gaap Share Price
SharePrice
4.11
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
13636000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4625000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
7700000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6899000
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29298558 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29298558 shares
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
290864000
CY2014Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
235000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12088000
CY2014Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
952000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
14924000
CY2014Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
249000
CY2014Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
37000
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
138000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
464000
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1524000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277013000
CY2014Q2 us-gaap Liabilities
Liabilities
7747000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22671000
CY2014Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5584000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
29000
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1890000
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2126000
CY2014Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35649000
CY2014Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
910000
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
1045000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1044000
CY2014Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30123000
CY2014Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
36559000
CY2014Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3079000
CY2014Q2 us-gaap Assets
Assets
22671000
CY2014Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2014Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2194000
CY2014Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
17204000
CY2014Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
517000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
297000
CY2014Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
0
CY2014Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
2944000
CY2014Q2 us-gaap Assets Current
AssetsCurrent
19342000
CY2014Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14260000
CY2014Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2944000
CY2014Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
88000
CY2014Q2 us-gaap Other Assets
OtherAssets
117000
CY2014Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2765000
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
547000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15334000
CY2014Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2187000
CY2014Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
2945000
CY2014Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
564000
CY2014Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses
511000
CY2014Q2 psdv Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
35649000
CY2014Q2 psdv Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
316000
CY2014Q2 psdv Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
3.67
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29412365 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29412365 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
482000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
482000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
293060000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1760000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
735000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
23368000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2015Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
384000
CY2015Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
55000
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
744000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2571000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-270666000
CY2015Q2 us-gaap Liabilities
Liabilities
8999000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32367000
CY2015Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5596000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
29000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
359000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1806000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3348000
CY2015Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32077000
CY2015Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
640000
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
950000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
945000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
437000
CY2015Q2 us-gaap Security Deposit
SecurityDeposit
150000
CY2015Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25736000
CY2015Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32717000
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1700000
CY2015Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3431000
CY2015Q2 us-gaap Assets
Assets
32367000
CY2015Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2194000
CY2015Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
25249000
CY2015Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
622000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
338000
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2015Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
0
CY2015Q2 us-gaap Assets Current
AssetsCurrent
29838000
CY2015Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
15835000
CY2015Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9414000
CY2015Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
110000
CY2015Q2 us-gaap Other Assets
OtherAssets
116000
CY2015Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
15800000
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1925000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
681000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19121000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2144000
CY2015Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1246000
CY2015Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses
0
CY2015Q2 psdv Collaboration Agreement Ownership Percentage In Company
CollaborationAgreementOwnershipPercentageInCompany
0.063 pure
CY2015Q2 psdv Estimated Annual Amortization Of Intangible Assets
EstimatedAnnualAmortizationOfIntangibleAssets
770000
CY2015Q2 psdv Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
32077000
CY2015Q2 psdv Cash And Cash Equivalents And Marketable Securities Fair Value
CashAndCashEquivalentsAndMarketableSecuritiesFairValue
28500000
CY2015Q2 psdv Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
1424000
CY2015Q2 psdv Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
3.67
CY2015Q2 psdv Domestic Federal Tax Benefit From Utilization Of Tax Loss Carry Forwards
DomesticFederalTaxBenefitFromUtilizationOfTaxLossCarryForwards
2500000
CY2011Q1 psdv Warrants Granted To Purchase Common Stock
WarrantsGrantedToPurchaseCommonStock
552500 shares
CY2011Q1 psdv Term Of Warrants
TermOfWarrants
P5Y
CY2013Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3494550 shares
CY2013Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
890000
CY2013Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10800000
CY2012Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2494419 shares
CY2012Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000
CY2012Q3 psdv Warrants Granted To Purchase Common Stock
WarrantsGrantedToPurchaseCommonStock
623605 shares
CY2012Q3 psdv Term Of Warrants
TermOfWarrants
P5Y
CY2012Q3 psdv Percentage Of Shares Of Common Stock Issued Under Terms Of Warrant Transactions
PercentageOfSharesOfCommonStockIssuedUnderTermsOfWarrantTransactions
0.25 pure
CY2012Q3 psdv Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
5400000
CY2012Q3 psdv Share Price Per Unit
SharePricePerUnit
2.15
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1700000 shares
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
191000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000
CY2013 us-gaap Revenues
Revenues
2143000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1317000
CY2013 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
7000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7000000
CY2014Q1 psdv Number Of Institutional Investors
NumberOfInstitutionalInvestors
1 Investor
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8745000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4730654 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.98 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23044152 shares
CY2013 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23044152 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0081 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.29
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0098 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.95 pure
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
68000
CY2013 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-364000
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7758000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-11900000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4669000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1272000
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
780000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-12031000
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
1363000
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11922000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-29000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12017000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
16000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
134000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10101000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1916000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-117000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1317000
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-117000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
35000
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
681000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
235000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1961000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
769000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
277000
CY2013 us-gaap Depreciation
Depreciation
225000
CY2013 psdv Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
231000
CY2013 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
-117000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-569000
CY2013 psdv Proceeds From Issuance Of Common Stock Net Of Share Issue Costs
ProceedsFromIssuanceOfCommonStockNetOfShareIssueCosts
4669000
CY2013 psdv Deferred Domestic Income Tax Expense Benefit
DeferredDomesticIncomeTaxExpenseBenefit
0
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
454000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2274000
CY2013 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2939000
CY2013 us-gaap Operating Expenses
OperatingExpenses
14174000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
6358000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4669000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7005000
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1288000
CY2013 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
0
CY2013 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
145000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1317000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7169000
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-8000
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
152000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4086000
CY2013 psdv Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0 shares
CY2013 psdv Domestic Income Tax Expense Benefit Continuing Operations
DomesticIncomeTaxExpenseBenefitContinuingOperations
0
CY2013 psdv Increase Decrease In Deferred Tax Assets Net
IncreaseDecreaseInDeferredTaxAssetsNet
2900000
CY2013 psdv Current Domestic Tax Expense Benefit
CurrentDomesticTaxExpenseBenefit
0
CY2013 psdv Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
0
CY2013 psdv Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
14184000
CY2013 psdv Income Tax Reconciliation Expiration Of State Net Operating Loss Carry Forwards
IncomeTaxReconciliationExpirationOfStateNetOperatingLossCarryForwards
706000
CY2013 psdv Income Tax Reconciliation Capital Loss Expirations
IncomeTaxReconciliationCapitalLossExpirations
0
CY2013 psdv Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
201000
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10671000
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4967106 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.96 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27443592 shares
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27443592 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0170 pure
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
248000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.48
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0199 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.94 pure
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27444000 shares
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2014 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-103000
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2964000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-13355000
CY2014 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
124000
CY2014 us-gaap Revenues
Revenues
3473000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1411000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18057000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1110000
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
2155000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-13490000
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
78000
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
1318000
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
150000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13231000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
124000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13485000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
169000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-11712000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1773000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-130000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1411000
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-130000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-267000
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
159000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
485000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8435000
CY2014 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4619000
CY2014 us-gaap Operating Expenses
OperatingExpenses
16963000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
66000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19044000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9573000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
78000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-381000
CY2014 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
987000
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
157000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
987000
CY2014 psdv Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
37000
CY2014 psdv Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
3350000
CY2014 psdv Income Tax Reconciliation Expiration Of State Net Operating Loss Carry Forwards
IncomeTaxReconciliationExpirationOfStateNetOperatingLossCarryForwards
161000
CY2014 psdv Income Tax Reconciliation Capital Loss Expirations
IncomeTaxReconciliationCapitalLossExpirations
0
CY2014 psdv Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
221000
CY2014 psdv Warrants To Purchase Common Shares Outstanding And Exercisable
WarrantsToPurchaseCommonSharesOutstandingAndExercisable
1176105 shares
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Operations</b></font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); PADDING-BOTTOM: 0px; FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">pSivida Corp. (together with its subsidiaries, the &#x201C;Company&#x201D;), incorporated in Delaware, develops sustained-release drug-delivery products for treating eye diseases. Its products deliver drugs at a controlled and steady rate for months or years. The Company has developed three of only four sustained-release products approved by the U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) for treatment of back-of-the-eye diseases. The most recent is ILUVIEN<font style="FONT-FAMILY: 'Times New Roman'" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>&#xA0;for diabetic macular edema (&#x201C;DME&#x201D;), sold by the Company&#x2019;s licensee in the U.S. and three European Union (&#x201C;EU&#x201D;) countries. The Company&#x2019;s lead product candidate, Medidur&#x2122; for posterior uveitis, is in pivotal Phase III clinical trials. The Company&#x2019;s pre-clinical development program is focused primarily on developing products for chronic ophthalmic diseases utilizing its core technology platforms.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">ILUVIEN is an injectable, sustained-release micro-insert that provides treatment of DME for three years from a single administration. ILUVIEN is licensed to Alimera Sciences, Inc. (&#x201C;Alimera&#x201D;), and the Company is entitled to a share of the net profits (as defined) from Alimera&#x2019;s sales of ILUVIEN. ILUVIEN was launched in late February 2015 in the U.S., where it is indicated for the treatment of DME in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure. ILUVIEN has been commercially available in the United Kingdom (&#x201C;U.K.&#x201D;) and Germany since June 2013 and in Portugal since January 2015. ILUVIEN has marketing approvals in these and 14 other EU countries for the treatment of chronic DME considered insufficiently responsive to available therapies. Distribution, regulatory and reimbursement matters for ILUVIEN for DME in Australia and New Zealand, Canada and Italy have been sublicensed.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Medidur, the Company&#x2019;s lead development product, is an injectable, micro-insert designed to treat chronic, non-infectious uveitis affecting the posterior of the eye (&#x201C;posterior uveitis&#x201D;) for three years from a single administration. Medidur, which is the same micro-insert as ILUVIEN, is in Phase III clinical trials, with the filing of a new drug application (&#x201C;NDA&#x201D;) anticipated in the first half of 2017. The Company is developing Medidur independently.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); PADDING-BOTTOM: 0px; FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company&#x2019;s FDA-approved Retisert<font style="FONT-FAMILY: 'Times New Roman'" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>&#xA0;provides sustained release treatment of posterior uveitis for approximately two and a half years. It is licensed to Bausch&#xA0;&amp; Lomb, and the Company receives royalties from its sales.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company&#x2019;s pre-clinical development program is focused on developing products using its core platform technologies, Durasert&#x2122; and Tethadur&#x2122;, to deliver drugs and biologics to treat wet and dry age-related macular degeneration (&#x201C;AMD&#x201D;), glaucoma, osteoarthritis and other diseases.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company has a history of operating losses and has financed its operations primarily from the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners, and from proceeds of sales of its equity securities. The Company believes that its cash, cash equivalents and marketable securities of $28.5 million at June&#xA0;30, 2015, together with expected cash inflows under existing collaboration agreements, will enable the Company to maintain its current and planned operations into early calendar year 2017. This estimate excludes any potential net profits receipts from sales of ILUVIEN under the Alimera collaboration agreement. The Company&#x2019;s ability to fund its planned operations beyond then, including completion of clinical development of Medidur, is expected to depend on the amount and timing of cash receipts from ILUVIEN net profits participation, as well as proceeds from any future collaboration or other agreements and/or financing transactions.</font></p> </div>
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
10297000
CY2014 psdv Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
189000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1411000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7468000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-4000
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
45000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4585000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
841000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
778000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-213000
CY2014 us-gaap Depreciation
Depreciation
139000
CY2014 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
-130000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-693000
CY2014 psdv Proceeds From Issuance Of Common Stock Net Of Share Issue Costs
ProceedsFromIssuanceOfCommonStockNetOfShareIssueCosts
18057000
CY2014 psdv Deferred Domestic Income Tax Expense Benefit
DeferredDomesticIncomeTaxExpenseBenefit
0
CY2014 psdv Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0 shares
CY2014 psdv Domestic Income Tax Expense Benefit Continuing Operations
DomesticIncomeTaxExpenseBenefitContinuingOperations
0
CY2014 psdv Increase Decrease In Deferred Tax Assets Net
IncreaseDecreaseInDeferredTaxAssetsNet
4600000
CY2014 psdv Current Domestic Tax Expense Benefit
CurrentDomesticTaxExpenseBenefit
0
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001314102
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2563293 shares
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Concentrations of Risk</b></font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. At June&#xA0;30, 2015, all of the Company&#x2019;s interest-bearing cash equivalent balances, aggregating $15.8 million, were concentrated in one institutional money market fund that has investments consisting primarily of certificates of deposit, commercial paper, time deposits and treasury repurchase agreements. Generally, these deposits may be redeemed upon demand and, therefore, the Company believes they bear minimal risk. Marketable securities at June&#xA0;30, 2015 and 2014 consisted of investment-grade corporate bonds and commercial paper. The Company&#x2019;s investment policy, approved by the Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Alimera Sciences accounted for $25.1 million, or 95% of total revenues in fiscal 2015 and inconsequential revenues in each of fiscal 2014 and fiscal 2013. Bausch&#xA0;&amp; Lomb accounted for $1.2 million, or 5% of total revenues in fiscal 2015, $1.3 million, or 38% of total revenues in fiscal 2014, and $1.4 million, or 64%, of total revenues in fiscal 2013. A completed feasibility study agreement accounted for $1.7 million, or 49%, of total revenues in fiscal 2014. Pfizer revenues, which were inconsequential in fiscal 2015 and fiscal 2014, accounted for $368,000, or 17%, of total revenues in fiscal 2013.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Bausch&#xA0;&amp; Lomb accounted for $371,000, or 60% of total accounts receivable at June&#xA0;30, 2015 and $302,000, or 58% of total accounts receivable at June&#xA0;30, 2014.</font></p> </div>
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.93 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Registrant Name
EntityRegistrantName
PSIVIDA CORP.
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30584140 shares
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
956441 shares
CY2015 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
235000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0170 pure
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29378250 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.33
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0200 pure
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenues and expenses during the reporting periods. Significant management estimates and assumptions include, among others, those related to revenue recognition for multiple-deliverable arrangements, recognition of expense in outsourced clinical trial agreements, recoverability of intangible assets, realization of deferred tax assets and the valuation of stock option awards. Actual results could differ from these estimates.</p> </div>
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
137000
CY2015 dei Trading Symbol
TradingSymbol
PSDV
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79 pure
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
161000
CY2015 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
124000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10222000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
6347000
CY2015 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-4000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-99000
CY2015 us-gaap Revenues
Revenues
26565000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1961000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
136000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
25411000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
6421000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
263000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
1154000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6248000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-95000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6443000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
19000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
313000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
8120000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1677000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
96000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1961000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-167000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-94000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
471000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
494000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3787000
CY2015 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3572000
CY2015 us-gaap Operating Expenses
OperatingExpenses
20144000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6733000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-12000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1053000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8056000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-5146000
CY2015Q2 us-gaap Revenues
Revenues
409000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5200000
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
98000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
263000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2191000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
257000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
770000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
292000
CY2015 us-gaap Depreciation
Depreciation
112000
CY2015 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
-167000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
435000
CY2015 psdv Proceeds From Issuance Of Common Stock Net Of Share Issue Costs
ProceedsFromIssuanceOfCommonStockNetOfShareIssueCosts
0
CY2015 psdv Deferred Domestic Income Tax Expense Benefit
DeferredDomesticIncomeTaxExpenseBenefit
0
CY2015 psdv Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
187000
CY2015 psdv Warrants Outstanding Weighted Average Remaining Contract Life
WarrantsOutstandingWeightedAverageRemainingContractLife
P1Y4M24D
CY2015 psdv Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
249449 shares
CY2015 psdv Domestic Income Tax Expense Benefit Continuing Operations
DomesticIncomeTaxExpenseBenefitContinuingOperations
263000
CY2015 psdv Increase Decrease In Deferred Tax Assets Net
IncreaseDecreaseInDeferredTaxAssetsNet
-1100000
CY2015 psdv Marketable Securities Weighted Average Maturity
MarketableSecuritiesWeightedAverageMaturity
P5M3D
CY2015 psdv Current Domestic Tax Expense Benefit
CurrentDomesticTaxExpenseBenefit
263000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
20566000
CY2015 psdv Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
18000
CY2015 psdv Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
3650000
CY2015 psdv Income Tax Reconciliation Expiration Of State Net Operating Loss Carry Forwards
IncomeTaxReconciliationExpirationOfStateNetOperatingLossCarryForwards
0
CY2015 psdv Income Tax Reconciliation Capital Loss Expirations
IncomeTaxReconciliationCapitalLossExpirations
511000
CY2015 psdv Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
236000
CY2015 psdv Class Of Warrant Or Right Period From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable
2013-02
CY2015 psdv Warrants To Purchase Common Shares Outstanding And Exercisable
WarrantsToPurchaseCommonSharesOutstandingAndExercisable
1176105 shares
CY2015 psdv Defined Contribution Plans Employee Contribution Percentage Of Eligible Compensation Matched By Employer
DefinedContributionPlansEmployeeContributionPercentageOfEligibleCompensationMatchedByEmployer
0.05 pure
CY2015 psdv Current Federal Tax Expense Before Utilization Of Operating Loss Carryforwards
CurrentFederalTaxExpenseBeforeUtilizationOfOperatingLossCarryforwards
2800000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27672000 shares
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2187000
CY2014Q1 us-gaap Revenues
Revenues
1992000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2219000
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29412000 shares
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29412000 shares
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-4998000
CY2015Q1 us-gaap Revenues
Revenues
328000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5052000
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2014Q4 us-gaap Revenues
Revenues
521000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4116000
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30765000 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29323000 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29256000 shares
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-3967000
CY2014Q2 us-gaap Revenues
Revenues
292000
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4012000
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29412000 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25918000 shares
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-3687000
CY2013Q3 us-gaap Revenues
Revenues
597000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3718000
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29412000 shares
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26953000 shares
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-3514000
CY2013Q4 us-gaap Revenues
Revenues
592000
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3541000
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29367000 shares
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29367000 shares
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-4075000
CY2014Q3 us-gaap Revenues
Revenues
25307000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
20789000

Files In Submission

Name View Source Status
0001193125-15-316983-index-headers.html Edgar Link pending
0001193125-15-316983-index.html Edgar Link pending
0001193125-15-316983.txt Edgar Link pending
0001193125-15-316983-xbrl.zip Edgar Link pending
d96257d10k.htm Edgar Link pending
d96257dex101.htm Edgar Link pending
d96257dex106.htm Edgar Link pending
d96257dex211.htm Edgar Link pending
d96257dex231.htm Edgar Link pending
d96257dex311.htm Edgar Link pending
d96257dex312.htm Edgar Link pending
d96257dex321.htm Edgar Link pending
d96257dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
psdv-20150630.xml Edgar Link completed
psdv-20150630.xsd Edgar Link pending
psdv-20150630_cal.xml Edgar Link unprocessable
psdv-20150630_def.xml Edgar Link unprocessable
psdv-20150630_lab.xml Edgar Link unprocessable
psdv-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending